Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - metotrexát - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - metotrexát - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

orion corporation, fínsko - metotrexát - 44 - cytostatica

Európska únia - slovenčina - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastické činidlá - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - eslikarbazepín - 21 - antiepileptica, anticonvulsiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - eslikarbazepín - 21 - antiepileptica, anticonvulsiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - eslikarbazepín - 21 - antiepileptica, anticonvulsiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - eslikarbazepín - 21 - antiepileptica, anticonvulsiva

Európska únia - slovenčina - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfóm, mantle-cell - antineoplastické činidlá - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Európska únia - slovenčina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastické činidlá - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.